| Capecitabine | CA Health Canada | — | Marketed in Canada as XELODA (DIN 02238453) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Dec 7, 2022 | Sep 10, 1998 | health-canada-dpd |
| Capecitabine | CA Health Canada | — | Marketed in Canada as MINT-CAPECITABINE (DIN 02508001) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| Capecitabine | CA Health Canada | — | Marketed in Canada as APO-CAPECITABINE (DIN 02434504) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| Capecitabine | CA Health Canada | — | Marketed in Canada as CAPECITABINE (DIN 02528150) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| Capecitabine | CA Health Canada | — | Marketed in Canada as CAPECITABINE (DIN 02528126) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| Capecitabine | CA Health Canada | — | Marketed in Canada as APO-CAPECITABINE (DIN 02434512) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| Capecitabine | EU EMA | — | Capecitabine is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer. Capecitabine is indicated for the treatment of metastatic colorectal cancer. Capecitabine is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. | withdrawnsince Jun 21, 2021 | Jun 21, 2013 | ema |
| Capecitabine | EU EMA | — | Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer. Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer. Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. | approved | Nov 19, 2012 | ema |
| Capecitabine | EU EMA | — | Capecitabine Teva is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer. Capecitabine Teva is indicated for the treatment of metastatic colorectal cancer. Capecitabine Teva is indicated for first?line treatment of advanced gastric cancer in combination with a platinum?based regimen. Capecitabine Teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. | approved | Apr 20, 2012 | ema |
| Capecitabine | EU EMA | — | Capecitabine Accord is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer. Capecitabine Accord is indicated for the treatment of metastatic colorectal cancer. Capecitabine Accord is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Capecitabine Accord in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Accord is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. | approved | Apr 20, 2012 | ema |
| Capecitabine | EU EMA | — | Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer. Ecansya is indicated for the treatment of metastatic colorectal cancer. Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. | approved | Apr 20, 2012 | ema |
| Capecitabine | EU EMA | — | Xeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer. Xeloda is indicated for the treatment of metastatic colorectal cancer. Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. | approved | Feb 2, 2001 | ema |
| Capecitabine | US FDA | — | Efficacy supplement 2022-12-14 (see label) | approved | Dec 14, 2022 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2022-12-14 (see label) | approved | Dec 14, 2022 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2022-12-14 (see label) | approved | Dec 14, 2022 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2022-12-14 (see label) | approved | Dec 14, 2022 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2022-12-14 (see label) | approved | Dec 14, 2022 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2022-12-14 (see label) | approved | Dec 14, 2022 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2022-12-14 (see label) | approved | Dec 14, 2022 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2022-12-14 (see label) | approved | Dec 14, 2022 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2013-12-10 (see label) | approved | Dec 10, 2013 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2011-02-05 (see label) | approved | Feb 5, 2011 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2005-06-15 (see label) | approved | Jun 15, 2005 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2001-09-07 (see label) | approved | Sep 7, 2001 | openfda |
| Capecitabine | US FDA | — | Efficacy supplement 2001-04-30 (see label) | approved | Apr 30, 2001 | openfda |
| Capecitabine | US FDA | Malignant Rectal Neoplasm | perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. | approved | Apr 30, 1998 | openfda |
| Capecitabine | US FDA | Malignant Colon Neoplasm | Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. | approved | Apr 30, 1998 | openfda |
| Capecitabine | US FDA | Malignant Colorectal Neoplasm | treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. | approved | Apr 30, 1998 | openfda |
| Capecitabine | US FDA | — | Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. | approved | Apr 30, 1998 | openfda |
| Capecitabine | US FDA | Malignant Breast Neoplasm | Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. | approved | Apr 30, 1998 | openfda |
| Capecitabine | US FDA | Malignant Breast Neoplasm | treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. | approved | Apr 30, 1998 | openfda |
| Capecitabine | US FDA | Gastroesophageal Junction Adenocarcinoma | treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. | approved | Apr 30, 1998 | openfda |
| Capecitabine | US FDA | Pancreatic Adenocarcinoma | Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. | approved | Apr 30, 1998 | openfda |
| Carboplatin | CA Health Canada | — | Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02320371) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Mar 11, 2015 | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as CARBOPLATIN INJECTION (DIN 02366053) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Dormantsince Jul 28, 2020 | Jun 10, 2013 | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02126680) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Jul 30, 1997 | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as CARBOPLATIN INJECTION (DIN 02125439) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Dec 31, 1994 | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as CARBOPLATIN INJECTION LIQ 10MG/ML (DIN 01990438) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Aug 13, 1998 | Dec 31, 1992 | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as PARAPLATIN-AQ INJ 10MG/ML (DIN 00788759) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Jul 30, 2007 | Dec 31, 1989 | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as PARAPLATIN INJ 150MG/VIAL (DIN 00680060) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Sep 9, 1996 | Dec 31, 1986 | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02570963) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as CARBOPLATIN INJECTION (DIN 02528916) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as CARBOPLATIN INJECTION, BP (DIN 02420228) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| Carboplatin | CA Health Canada | — | Marketed in Canada as CARBOPLATIN INJECTION (DIN 02535289) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| Carboplatin | US FDA | Ovarian Carcinoma | As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy. | approved | Aug 8, 2025 | openfda |
| Carboplatin | US FDA | Ovarian Carcinoma | As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. | approved | Aug 8, 2025 | openfda |
| Cetuximab | CA Health Canada | — | Marketed in Canada as ERBITUX (DIN 02271249) under ATC L01FE01 CETUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Oct 28, 2008 | health-canada-dpd |
| Cetuximab | EU EMA | — | Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in combination with irinotecan-based chemotherapy; in first-line in combination with FOLFOX; as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. For details, see section 5.1. Erbitux is indicated for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer: in combination with encorafenib and FOLFOX for the first line treatment; in combination with encorafenib in patients who have received prior systemic therapy. For details, see section 5.1, for biomarker-based patient selection, see section 4.2. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck: in combination with radiation therapy for locally advanced disease; in combination with platinum-based chemotherapy for recurrent and/or metastatic disease. | approved | Jun 29, 2004 | ema |
| Cetuximab | US FDA | — | Efficacy supplement 2021-09-24 (see label) | approved | Sep 24, 2021 | openfda |
| Cetuximab | US FDA | — | Efficacy supplement 2021-04-06 (see label) | approved | Apr 6, 2021 | openfda |